ReviewCancer management and research2018
A review of soft-tissue sarcomas: translation of biological advances into treatment measures.
Review in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed.
- Ultrasound-Guided Histotripsy for Non-Invasive Treatment of Ex Vivo Soft Tissue Tumors: Preclinical Feasibility Study.Annals of surgical oncology · 2026Article
- Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application.Journal of surgical oncology · 2026Review
- Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach.Current treatment options in oncology · 2026Review
- Cutaneous angiosarcoma in a super-morbidly obese patient (body mass index 106.7 kg/mJournal of medical case reports · 2026Article
- MRI features outperform histologic grade for outcome prediction in translocation-driven enriched soft-tissue sarcoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review.Pharmaceuticals (Basel, Switzerland) · 2026Article
- A proposed radiological model for preoperative chemotherapy response prediction in patients with skeletal Ewing sarcoma.Skeletal radiology · 2026Article
- Choosing the right animal model for sarcoma research.Cellular and molecular life sciences : CMLS · 2026Review
- A unified model for Duchenne muscular dystrophy gene involvement in cancer: context-dependent tumour suppression and oncogenicity.FEBS open bio · 2026Article
- Dermatofibrosarcoma Protuberans (DFSP): Diagnostics and Molecular Pathology.Current treatment options in oncology · 2025Review
- Epigenetic paradigm of DNA methylation for understanding the pathophysiology, diagnostics, and therapeutics in sarcomas.Epigenomics · 2025Review
- Hypoxia-driven metastatic progression in synovial sarcoma: insights from SYO-1 and SW982 models.BMC cancer · 2025Article
- Synovial Sarcoma of Testis: a Rare Tumour at an Uncommon Site-A Case Report.Indian journal of surgical oncology · 2025Article
- Neoadjuvant Immunotherapy for Resectable Dedifferentiated Liposarcoma: A National Cohort Analysis.Journal of surgical oncology · 2025Article
- Article
- Anti-Tumor Effect of Non-Thermal Atmospheric Pressure Plasma-Activated Medium on Synovial Sarcoma: An In Vitro and In Vivo Study.Biomedicines · 2025Article
- Biosponge-Encased Placental Stem Cells for Volumetric Muscle Loss Repair.Advances in wound care · 2025Article
- Article
- Physical Activity and Quality of Life After Distal Femur Tumor Resection and Limb Salvage.Journal of functional morphology and kinesiology · 2024Article
- A reduction in tumor volume exceeding 65% predicts a good histological response to neoadjuvant chemotherapy in patients with Ewing sarcoma.Skeletal radiology · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft-tissue sarcomas are rare malignant tumors arising from connective tissues and have an overall incidence of about five per 100,000 per year. While this diverse family of malignancies comprises over 100 histological subtypes and many molecular aberrations are prevalent within specific sarcomas, very few are therapeutically targeted. Instead of utilizing molecular signatures, first-line sarcoma treatment options are still limited to traditional surgery and chemotherapy, and many of the latter remain largely ineffective and are plagued by disease resistance. Currently, the mechanism of sarcoma oncogenesis remains largely unknown, thus necessitating a better understanding of pathogenesis. Although substantial progress has not occurred with molecularly targeted therapies over the past 30 years, increased knowledge about sarcoma biology could lead to new and more effective treatment strategies to move the field forward. Here, we discuss biological advances in the core molecular determinants in some of the most common soft-tissue sarcomas - liposarcoma, angiosarcoma, leiomyosarcoma, rhabdomyosarcoma, Ewing's sarcoma, and synovial sarcoma - with an emphasis on emerging genomic and molecular pathway targets and immunotherapeutic treatment strategies to combat this confounding disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.